App-Quantinova.ai

Prognostic Value of Circulating Tumor Cells in Patients With Small Cell Lung Cancer Receiving Front-Line Treatment

H. Zhu - IASLC World Conference on Lung Cancer (IASLC WCLC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Small cell lung cancer

Etoposide

Targeted RNA-seq signature of breast cancer (BC) circulating tumor cells (CTCs) correlates with the onset of bone-only metastases

Stella D'oronzo - European Calcified Tissue Society (ECTS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Cerebello-Thalamo-Cortical Hyperconnectivity Classifies Patients and Predicts Long-Term Treatment Outcome in First-Episode Schizophrenia

Hengyi Cao - Society of Biological Psychiatry (SOBP) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Schizophrenia

N/A

CIRCULATING TUMOR CELLS (CTC) ARE THE MOST RELEVANT DIAGNOSTIC BIOMARKER IN TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA (MM)

Juan-Jos Garcs - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

Ixazomib

BELINOSTAT IS WELL TOLERATED AND EFFICACIOUS IN A PATIENT WITH EARLY RELAPSED PERIPHERAL T-CELL LYMPHOMA: A CASE REPORT.

Michele Cimminiello - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Peripheral T-cell lymphoma

belinostat Intravenous

Platelet and immune cell cloaking of circulating tumour cells [CTCs] in breast and ovarian cancer

M. Ward - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Gynaecological cancer

N/A

Identification of PD-L1 expression on circulating tumor cells as a prognostic indicator in prospective clinical trial, OMNIVORE

Rory M. Bade - American Association for Cancer Research (AACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Renal cell carcinoma

Ipilimumab

Detection of EGFR mutations in plasma cfDNA and paired CTCs of NSCLC patients before and after osimertinib therapy using crystal digital PCR

Aliki Ntzifa - American Association for Cancer Research (AACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Lung Cancer

Tagrisso

Blood-based biomarker analysis for predicting efficacy of definitive concurrent chemoradiotherapy and durvalumab consolidation in patients with unresectable locally advanced non-small cell lung cancer

Cheol-Kyu Park - American Association for Cancer Research (AACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

Durvalumab

Longitudinal transcriptional profiling of CTCs in metastatic breast cancer patients receiving CDK4/6 inhibitors to predict response

Corinna Keup - American Association for Cancer Research (AACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Palbociclib

Deciphering melanoma CTC signatures leading to immune escape and brain metastasis: The first MRI CTC xenograft model

Tetiana Bowley - American Association for Cancer Research (AACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Melanoma

N/A

Microfluidic characterization of circulating tumor cells from mouse models and patients with head and neck cancer

Matt C. Mannino - American Association for Cancer Research (AACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Squamous cell carcinoma of the head and neck

N/A

Establishing circulating tumor cell-derived xenografts following a period of in vitro culture

Jerry Xiao - American Association for Cancer Research (AACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Lung Cancer

N/A

Isolation of viable circulating tumor cells from peripheral and central venous blood using a rapid microfluidic biochip

Jian Zhou - American Association for Cancer Research (AACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Development and analytical validation of a highly sensitive and specific NAPA assay for the detection of ESR1mutations in circulating tumor cells and plasma circulating tumor DNA

Dimitra Stergiopoulou - American Association for Cancer Research (AACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Enhanced isolation of circulating tumor cells from leukapheresis material enabled by Akadeum microbubbles

Edward Grimley - American Association for Cancer Research (AACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

A pharmacodynamic platform using liquid biopsy to support dose selection for the ATR inhibitor ART0380 (IACS-030380

Manish Patel - American Association for Cancer Research (AACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Ataxia telangiectasia

N/A

Surgery versus IVF/ICSI in infertile women with rectosigmoid endometriosis: the FERTILITY-RECTOSIGMOID study

F Barra - European Society for Human Reproduction and Embryology (ESHRE) , 2022

Therapeutic Area

Disease

Drug/Treatment

Obstetrics/Gynecology

Endometriosis

N/A

Chromosomal instability (CIN) in circulating tumor cells (CTC) predicts for taxane sensitivity in metastatic castration-resistant prostate cancer (mCRPC).

Niamh M. Keegan - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2022

Therapeutic Area

Disease

Drug/Treatment

Urology

Metastatic castration-resistant prostate cancer

taxane

Circulating tumour cells (CTCs) and PSMA PET correlates in the phase I PRINCE trial of 177Lu-PSMA-617 plus pembrolizumab for metastatic castration resistant prostate cancer (mCRPC).

Anis Hamid - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2022

Therapeutic Area

Disease

Drug/Treatment

Urology

Metastatic castration-resistant prostate cancer

Pembrolizumab

Filters

1671 Abstracts